(Q28245682)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

María I Domínguez-Mozo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Roberto Alvarez-Lafuente

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

Rafael Pelaez Lamamie De Clairac Arroyo

2 June 2020

7

object named as

Rafael Arroyo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

5

Ana Maria Arias-Leal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Isabel Ortega-Madueño

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Angel Garcia-Martinez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Ignacio Casanova

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

2014

0 references

published in

PLOS One

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

e104836

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

2 June 2020

copyright license

start time

11 August 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Interferons at age 50: past, current and future impact on biomedicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Anti-viral properties of interferon beta treatment in patients with multiple sclerosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Plaque-associated expression of human herpesvirus 6 in multiple sclerosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Evidence for viral etiology of multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Immunogenicity of interferon beta: differences among products

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

The historical development of interferons as multiple sclerosis therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4128748

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104836

Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104836

Human Herpesvirus 6 Genome and Antigen in Acute Multiple Sclerosis Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104836

Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104836

Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104836

Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104836

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104836

Epstein-Barr virus and multiple sclerosis

21 January 2018

1 reference

12 December 2020

MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients

1 reference

12 December 2020

Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study

1 reference

12 December 2020

Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients

1 reference

12 December 2020

Beta-interferon treatment reduces human herpesvirus-6 viral load in multiple sclerosis relapses but not in remission

1 reference

12 December 2020

Quantitation of neutralization of interferon by antibody

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0104836

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

PubMed publication ID

25110949

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25110949%20AND%20SRC:MED&resulttype=core&format=json